RT Journal Article
SR Electronic
T1 Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.24.22272904
DO 10.1101/2022.03.24.22272904
A1 Campos, Guilherme R. F.
A1 Almeida, Nathalie Bonatti Franco
A1 Filgueiras, Priscilla Soares
A1 Corsini, Camila Amormino
A1 Gomes, Sarah Vieira Contin
A1 de Miranda, Daniel Alvim Pena
A1 de Assis, Jéssica Vieira
A1 Silva, Thaís Bárbara de Souza
A1 Alves, Pedro Augusto
A1 Fernandes, Gabriel da Rocha
A1 de Oliveira, Jaquelline Germano
A1 Rahal, Paula
A1 Queiroz, Rafaella Fortini Grenfelle
A1 Nogueira, Maurício L.
YR 2022
UL http://medrxiv.org/content/early/2022/03/25/2022.03.24.22272904.abstract
AB The emergence of the new SARS-CoV-2 Omicron variant, which is known to accumulate a huge number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. In this scenario, we evaluated the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. The percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 17% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times, indicating a positive impact of this vaccine combination in the serological immune response.Competing Interest StatementMLN has received research grants from Instituto Butantan, Janssen Vaccines & Prevention B.V., Medicago R&D Inc, and Pfizer/BioNTech SE. The other authors declare that there is no competing interest to disclosure at this time.Funding StatementThis study was funded by Oswaldo Cruz Foundation (Inova Fiocruz Program); GRFC is supported by FAPESP (2020/07419-0); MLN is partly funded by the Centers for Research in Emerging Infectious Diseases (CREID), The Coordinating Research on Emergng Arboviral Threats Encompassing the Neotropics (CREATE-NEO) grant U01 AI151807 by the National Institutes of Health (NIH/USA); MLN is supported by a FAPESP COVID Grant (2020/04836-0); MLN is a Brazilian National Council for Scientific and Technological Development (CNPQ) Research Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Oswaldo Cruz Foundation Ethics committee (Fiocruz CAAE) waived ethical approval for this work (approval number 42898621.9.0000.5091)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript